TORONTO, ON / ACCESSWIRE / March 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug Administration (FDA) have agreed on the primary endpoint and population for a pivotal Phase 3 study evaluating Edesa's monoclonal antibody candidate, EB05, as a therapy for hospitalized patients with a severe form of respiratory failure. The FDA recently granted the program Fast Track designation.
Health Canada has granted approval to Edesa Biotech for a Phase II clinical trial of its EB06 monoclonal antibody candidate to treat vitiligo, a life-altering autoimmune disease.
MARKHAM, Ontario, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that his beneficial ownership of common shares (“Common Shares”) in the capital of Edesa Biotech, Inc. (“Edesa”) has increased by more than 2% of the issued and outstanding Common Shares from the amount reported in the early warning report Dr. Nijhawan filed dated September 18, 2020 (the “Previous Report”).
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.
TORONTO, ON / ACCESSWIRE / December 1, 2021 /Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.
TORONTO, ON / ACCESSWIRE / October 19, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.
The doubling in value of tiny Edesa Biotech yesterday on mid-stage Covid-19 data in a handful of patients shows that there is still interest in new therapies for the coronavirus, particularly in the inpatient setting.
Shares of Edesa Biotech (EDSA -20.3%) are down significantly, just a day after they closed ~39% higher following positive results of its phase 2 COVID-19 antibody candidate EB05.